InflaRx (IFRX) Exchange Rate Effect (2016 - 2026)
InflaRx (IFRX) posted Exchange Rate Effect of $351429.7 for Q1 2026, up 427.37% sequentially from -$107348.1 in Q4 2025, and up 119.21% YoY from $160313.5 in Q1 2025.
InflaRx (IFRX) Exchange Rate Effect (2016 - 2026) Analysis & Trends
InflaRx has reported Exchange Rate Effect for 11 years, with the latest figure at $351429.7 in Q1 2026.
- Quarterly Exchange Rate Effect rose 119.21% year-over-year to $351429.7 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$1.7 million (down 148.49% YoY) and the FY2025 annual result came in at -$4.1 million, down 364.98% from the prior year.
- Exchange Rate Effect rose to $351429.7 in Q1 2026 per IFRX's latest filing, from -$107348.1 in the prior quarter.
- Over five years, Exchange Rate Effect peaked at $2.0 million in Q2 2022 and troughed at -$2.0 million in Q2 2025.
- A 5-year average of -$29687.7 and a median of -$40102.1 in 2025 frame the typical range for Exchange Rate Effect.
- The sharpest annual moves came in 2024 and 2025: Exchange Rate Effect jumped 463.79% in 2024, then slumped 710.66% in 2025.
- Over 5 years, Exchange Rate Effect stood at -$523806.2 in 2022, then plunged by 60.92% to -$842905.3 in 2023, then surged by 281.52% to $1.5 million in 2024, then slumped by 107.02% to -$107348.1 in 2025, then soared by 427.37% to $351429.7 in 2026.
- According to Business Quant data, Exchange Rate Effect over the past three periods registered $351429.7, -$107348.1, and -$40102.1 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Exchange Rate Effect (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.66 Bn | 131.80 Bn | 2.84 Bn | -3.70 Mn |
| 2 | Regeneron Pharmaceuticals | 86.52 Bn | 78.53 Bn | 3.93 Bn | -300,000.00 |
| 3 | Argenx Se | 65.33 Bn | 60.14 Bn | 1.37 Bn | - |
| 4 | Moderna | 59.76 Bn | 54.62 Bn | 52.00 Mn | -2.00 Mn |
| 5 | BeOne Medicines | 42.15 Bn | 37.05 Bn | 1.53 Bn | 19.84 Mn |
| 6 | Alnylam Pharmaceuticals | 31.84 Bn | 28.53 Bn | 992.69 Mn | -2.45 Mn |
| 7 | BioNTech SE | 28.23 Bn | 9.84 Bn | 668.28 Mn | 1.63 Mn |
| 8 | Insmed | 27.52 Bn | 26.36 Bn | 358.27 Mn | -287,000.00 |
| 9 | Royalty Pharma | 27.29 Bn | 26.46 Bn | - | - |
| 10 | InflaRx | 141.98 Mn | -42.27 Mn | 2.74 Bn | 2.32 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 351,429.75 |
| Mar 31, 2026 | 351,429.75 |
| Dec 31, 2025 | -107,348.09 |
| Dec 31, 2025 | -107,348.09 |
| Sep 30, 2025 | -40,102.10 |
| Sep 30, 2025 | -40,102.10 |
| Jun 30, 2025 | -1.95 Mn |
| Jun 30, 2025 | -1.95 Mn |
| Mar 31, 2025 | -1.83 Mn |
| Mar 31, 2025 | -1.83 Mn |
| Dec 31, 2024 | 1.53 Mn |
| Dec 31, 2024 | 1.53 Mn |
| Sep 30, 2024 | -723,771.68 |
| Sep 30, 2024 | -723,771.68 |
| Jun 30, 2024 | 319,540.54 |
| Jun 30, 2024 | 319,540.54 |
| Mar 31, 2024 | 374,122.35 |
| Mar 31, 2024 | 374,122.35 |
| Dec 31, 2023 | -842,905.31 |
| Dec 31, 2023 | -842,905.31 |